Genetic Variants in Patients With a Family History of Pancreatic Cancer: Impact of Multigene Panel Testing

Conclusions Genetic testing of individuals with a FH of pancreatic cancer represents an opportunity to identify individuals who may be candidates for pancreatic surveillance.
Source: Pancreas - Category: Gastroenterology Tags: Original Articles Source Type: research

Related Links:

Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Conditions:   Periampullary Cancer;   Pancreatic Fistula;   Bleeding Intervention:   Procedure: Pancreaticoduodenectomy Sponsor:   Vo Truong Quoc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This study reported that the combined use of pan-peroxisome proliferator-activated receptor (PPAR) agonist could significantly improve the anti-PC effect of EZH2 inhibitor. In vitro, PC cell lines PANC-1 and AsPC-1 were cultured, and MTT and flow cytometry were performed to observe the effects of pan-PPAR agonist bezafibrate and EZH2 selective inhibitor GSK126 on cell viability and apoptosis. In vivo, CDXs of PANC-1 and AsPC-1 were established to observe the effects of bezafibrate and GSK126 on bearing tumors. Western blotting was performed to detect the protein expressions of H3K27me3, β-catenin, p-β-catenin, cy...
Source: PPAR Research - Category: Genetics & Stem Cells Authors: Source Type: research
CONCLUSIONS: Anorexia, pain and peripheral neuropathy were significantly associated with a decrease in QOL. It is assumed that appropriate pharmaceutical intervention with particular emphasis on these AEs can improve the QOL of pancreatic cancer patients receiving outpatient chemotherapy.PMID:34334136 | DOI:10.1186/s40780-021-00210-1
Source: Pain Physician - Category: Anesthesiology Authors: Source Type: research
CONCLUSION: The findings suggest an association between the use of statins and non-selective beta-blockers and reduced pancreatic cancer mortality, and add to the literature supporting the design of randomised clinical trials to evaluate those drugs in the management of pancreatic cancer.PMID:34338111 | DOI:10.1080/0284186X.2021.1953136
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Source Type: research
This study aimed to develop and validate a radiomics model to discriminate patients with pancreatic cancer and liver metastases from those with other metastatic patterns.METHODS: We evaluated 77 patients who had APC and performed texture analysis on the region of interest. 58 patients and 19 patients were allocated randomly into the training and validation cohorts with almost the same proportion of liver metastases. An independentsamples t-test was used for feature selection in the training cohort. Random forest classifier was used to construct models based on these features and a radiomics signature (RS) was derived. A no...
Source: Cancer Biomarkers - Category: Cancer & Oncology Authors: Source Type: research
This study reported that the combined use of pan-peroxisome proliferator-activated receptor (PPAR) agonist could significantly improve the anti-PC effect of EZH2 inhibitor. In vitro, PC cell lines PANC-1 and AsPC-1 were cultured, and MTT and flow cytometry were performed to observe the effects of pan-PPAR agonist bezafibrate and EZH2 selective inhibitor GSK126 on cell viability and apoptosis. In vivo, CDXs of PANC-1 and AsPC-1 were established to observe the effects of bezafibrate and GSK126 on bearing tumors. Western blotting was performed to detect the protein expressions of H3K27me3, β-catenin, p-β-catenin, cy...
Source: Cell Research - Category: Cytology Authors: Source Type: research
This study aimed to develop and validate a radiomics model to discriminate patients with pancreatic cancer and liver metastases from those with other metastatic patterns.METHODS: We evaluated 77 patients who had APC and performed texture analysis on the region of interest. 58 patients and 19 patients were allocated randomly into the training and validation cohorts with almost the same proportion of liver metastases. An independentsamples t-test was used for feature selection in the training cohort. Random forest classifier was used to construct models based on these features and a radiomics signature (RS) was derived. A no...
Source: Cancer Biomarkers : Section A of Disease Markers - Category: Cancer & Oncology Authors: Source Type: research
Series Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensPancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers that lack effective therapeutic options. Here we show that the transcription factor Homeobox C6 (HOXC6) is overexpressed in PDAC and its inhibition blocks PDAC tumor growth and metastasis. By analyzing the HOXC6 shRNA expressing PDAC cells by RNA-sequencing, we identified PPP2R2B and MSK1 as key downstream mediators of HOXC6 function in PDAC. HOXC6 represses PPP2R2B to activate mTOR pathway in PDAC, which in part is necessary for HOXC6-loss induced PDAC inhibition. A...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Cell Death &Disease, Published online: 02 August 2021; doi:10.1038/s41419-021-03985-1Oncogene APOL1 promotes proliferation and inhibits apoptosis via activating NOTCH1 signaling pathway in pancreatic cancer
Source: Cell death and disease - Category: Internal Medicine Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Gastroenterology | Genetics | Pancreas | Pancreatic Cancer | Study